Zheng Xiao, Song Xing, Shao Yingjie, Xu Bin, Hu Wenwei, Zhou Qi, Chen Lujun, Zhang Dachuan, Wu Changping, Jiang Jingting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China.
Cell Physiol Biochem. 2018;45(2):720-732. doi: 10.1159/000487164. Epub 2018 Jan 31.
BACKGROUND/AIMS: Several studies have verified the correlation between tumor-infiltrating lymphocytes (TILs) and survival of patients with esophagus cancer (EC). However, the prognostic role of TILs is still controversial. Therefore, we performed this meta-analysis.
We searched PubMed, Embase and the Cochrane Library (last update by August 30, 2017) to identify studies assessing the effect of TILs on survival of patients with EC. Pooled hazard ratios (HRs) for overall survival (OS), disease-free survival (DFS) and cancer specific survival (CSS) were estimated using fixed-effects models or random-effects models, which depends on the heterogeneity.
Data from 22 observational studies including 2909 patients were summarized. Pooled analysis indicated that generalized TILs were favorable prognostic markers for OS in patients with EC (pooled HR = 0.48; 95% CI = 0.38-0.61; P < 0.001). For TIL subsets, CD8+ TILs were associated with improved OS (pooled HR = 0.68; 95% CI = 0.58-0.84; P < 0.001) and DFS (pooled HR = 0.90; 95% CI = 0.85-0.95; P < 0.001); FoxP3+ TILs were associated with patients' DFS (pooled HR = 0.88; 95% CI = 0.81-0.96; P = 0.003). High CD57+ TILs indicated a better OS in patients with EC (pooled HR = 0.50; 95% CI = 0.35-0.72; P < 0.001). In addition, the pooled results showed that other TIL subsets including CD3+, CD4+ and CD45RO+ TILs were not associated with patients' survival (P > 0.05).
For patients with EC, some TIL subsets could serve as prognostic biomarkers. The application of TILs in the immunotherapy of EC needs to be verified through a large amount of clinical research.
背景/目的:多项研究已证实肿瘤浸润淋巴细胞(TILs)与食管癌(EC)患者生存率之间的相关性。然而,TILs的预后作用仍存在争议。因此,我们进行了这项荟萃分析。
我们检索了PubMed、Embase和Cochrane图书馆(截至2017年8月30日的最新更新),以确定评估TILs对EC患者生存影响的研究。根据异质性情况,使用固定效应模型或随机效应模型估计总生存期(OS)、无病生存期(DFS)和癌症特异性生存期(CSS)的合并风险比(HRs)。
汇总了来自22项观察性研究(共2909例患者)的数据。汇总分析表明,广义TILs是EC患者OS的良好预后标志物(合并HR = 0.48;95%CI = 0.38 - 0.61;P < 0.001)。对于TIL亚群,CD8 + TILs与OS改善(合并HR = 0.68;95%CI = 0.58 - 0.84;P < 0.001)和DFS改善(合并HR = 0.90;95%CI = 0.85 - 0.95;P < 0.001)相关;FoxP3 + TILs与患者DFS相关(合并HR = 0.88;95%CI = 0.81 - 0.96;P = 0.003)。高CD57 + TILs表明EC患者OS较好(合并HR = 0.50;95%CI = 0.35 - 0.72;P < 0.001)。此外,汇总结果显示,包括CD3 +、CD4 +和CD45RO + TILs在内的其他TIL亚群与患者生存无关(P > 0.05)。
对于EC患者,一些TIL亚群可作为预后生物标志物。TILs在EC免疫治疗中的应用需要通过大量临床研究来验证。